Founded in September of 2016, Prime Gene Therapeutics Co.,Ltd. (“PrimeGene”, Stock code: 873969.NQ) is a company engaged in clinical stage innovative drug research and development focusing on immune-inflammatory diseases, oriented by the unmet clinical needs and featured by drugs for external use.

The founding team of PrimeGene is comprised of Li Yuliang (President, an entrepreneur with more than 20 years of industrial operation and management experience) and Du Yunlong (General Manager, an industrial scientist having worked for MNCs for years like Pfizer and GSK). The core teams of the Company all have rich experience in new drug research and development, clinical research and product launching at home and abroad. The Company also has attracted many well-known institutional investors to join in for its fast development, including K2 Venture Partners, Yuhang Longpan, and Sunland.

PrimeGene has established a sound innovative drug research and development system in reliance upon the experienced research and development team, and its product lines cover dermopathic, ophthalmic, respiratory diseases and membranous nephropathy for which the clinical needs are still unmet. Up to now, the company's core product PG-011 (Pumecitinib) Gel has completed the treatment of mild to moderate atopic dermatitis in adults in phase IIb clinical trials and entered the phase III clinical trial stage, the results of the phase IIb clinical study showed that the PG-011 gel topical administration in the treatment of adults with mild and moderate atopic dermatitis has shown significant effectiveness and good The company is exploring the efficacy and safety evaluation of this product in the treatment of mild to moderate atopic dermatitis in adolescents; PG-011 gel has completed a phase II clinical trial for the treatment of nodular itchy rash; PG-011 nasal spray is undergoing phase II clinical trials for the treatment of allergic rhinitis; PG-018 oral administration is undergoing phase I clinical trials for the treatment of membranous nephropathy; PG-011 gel is undergoing phase I clinical trials for the treatment of membranous nephropathy; PG-011 gel is undergoing phase I clinical trials for the treatment of membranous nephropathy. PG-011 gel for herpetic epidermolysis bullosa and non-segmental vitiligo is about to conduct phase II clinical trials, and clinical studies for the treatment of solar dermatitis and radiation dermatitis are in the preparation stage. In addition, the company has a number of leading potential products in the preclinical stage of research and development. Available data shows that the Company’s candidate compounds are significantly superior to similar competitive products in respect of biological activity, curative effect and safety, and it is placed in the first echolon in terms of the progress of researching and developing, creating great commercial competitive advantages for the Company’s product launching. Presently, the Company has a plenty of products at preclinical development stage, which lays a good stable foundation for sustainable healthy development of the Company. Regarding research and development of drugs, the Company is actively drafting an overall arrangement on patent in China and overseas. So far, it owns 9 invention patents and 14 articles.

Through years of development and accumulation, the Company has established a sound new drug research and development system from front-end study to back-end clinical development, built core technologies covering design and discovery of innovative small molecule drugs with computer-aided design technology, and explored a new compound technique of clinical value based on intensive study on targets and diseases, immune and inflammatory disease target verification technique, new drug molecular screening and evaluation technique, and external preparation development technique inclusive of hydrogel, ointment, emulsifiable paste, nasal spray, and eye drop, helping raising the success rate of the Company’s products under research and shortening drug research and development period via precise screening of drug targets, design and optimization of pharmaceutical molecules, evaluation and establishment of candidate drugs, chemical synthesis process, preparation development, and design and development of clinical plans. By virtue of powerful innovation and R&D capabilities, PrimeGene has obtained multiple technical certification and government support. The Company has been rated as a national new high-tech enterprise and “specialized, fine, characteristic, novel” middle and small-sized enterprise, recognized by Beijing Municipal Science & Technology Commission as a “scientific and technological R&D institute in Beijing Municipality”, identified as Gold Seed Enterprise in Zhongguancun Science Park and Zhongguancun High and New Enterprise, awarded with AAA Enterprise Credit Rating Certificate, and obtained subsidies under the Measures of Zhongguancun Fengtai Science Park for Supporting the Development and Scientific and Technological Innovation of High-grade, High-precision, Advanced Industries for two consecutive years from 2019 to 2020.

PrimeGene always sticks to the mission of “benefit patients, pray for health”, constantly enhances the construction of its capability of independent innovation and development, and strives to serve the world while solidifying its basis in China by further enriching product lines while steadily advancing research and development of existing products, with a view to building PrimeGene into a domestically leading and globally competitive innovative medical company with clinical advantages to make a contribution to human health.